

AGENDA

North of Tyne, Gateshead and North Cumbria Area Prescribing Committee www.northoftyneapc.nhs.uk Tuesday 18th April 2023 12:30 pm Click here to join the meeting		
1.	Apologies for absence Sharon Scully Chris Coe Geraint Morris	
2.	Declarations of interest	
3.	Appeals against previous decisions: None	
4.	Minutes from the meeting 10/01/23 Decision summary from 10/01/23	Enc.1. Enc.2.
5.	Matters arising not on the agenda	
6.	APC Action log <ul style="list-style-type: none"> • March update 	Enc.3.
7.	Report from the Formulary sub-group	Enc.4.
8.	Report from the Medicines Guidelines and Use Group <ul style="list-style-type: none"> • Draft minutes from meeting held on 6/3/23 • Guidance/documents for approval: <ul style="list-style-type: none"> ○ Urology- minor amendments (page 16 further addition to aid prescribing) ○ Trans anal irrigation- minor amendments (NCIC bladder team name change) ○ Methylphenidate in giggle incontinence - minor amendments (amber removed at beginning and IR prescribed generically) ○ Melatonin for sleep wake disorders – minor amendments (statement added (in blue)) ○ Nebulised gentamicin- minor amendments (NoTGNC name changed) ○ Paediatric renal transplant ○ Cinacalcet ○ Methylphenidate in narcolepsy– approved during meeting ○ CMPA- to be sent separately- awaiting pricing details • Guidance to retire: <ul style="list-style-type: none"> ○ Opioid statement (being updated and going to ICB meds committee for regional approval) • Guidance to extend: <ul style="list-style-type: none"> ○ Bariatric guideline 12 months from current review date ○ Children's ADHD 12 months from current review date ○ 	Enc.5. Enc.6. Enc.7. Enc.8. Enc.9. Enc.10. Enc.11. Enc.12. Enc.13. t/f
9.	Opiate/pain management sub-group <ul style="list-style-type: none"> • Notes from meeting on 16/3/23 • Quarter 3 data 	Enc.14. Enc.15.

10.	<p>NENC Medicines committee Approvals from February</p> <ul style="list-style-type: none"> • Medicines Committee North East and North Cumbria NHS (northeastnorthcumbria.nhs.uk) 	
11.	<p>NTAG The North East and North Cumbria (NENC) Medicines Committee are seeking NENC system-wide views on:</p> <ul style="list-style-type: none"> • The adoption of two shared care protocols: <ul style="list-style-type: none"> ○ Amiodarone ○ Sativex <p>The consultations are open until 5pm on Sunday 30th April 2023 and can be accessed at https://ntag.nhs.uk/consultations/.</p> • The adoption of proposed formulary amendments covering NICE Technology Appraisals and other relevant guidance and alerts published in March 2023. The consultation is open until 5pm on Thursday 4th May 2023 and can be accessed at https://ntag.nhs.uk/consultations/. 	
12.	<p>NHS England</p> <ul style="list-style-type: none"> • Specialised Services circulars: to be captured by NTAG <ul style="list-style-type: none"> ○ SSC2464 – Avacopan Provider Letter - NICE Technology Appraisal Guidance TA825 Avacopan NENC ○ SSC2465 – NICE TA FAD Guidance trastuzumab deruxtecan for treating HER2 ○ SSC2466 – NICE TA FAD - regorafenib for previously treated metastatic colorectal cancer ○ SSC2467 – Palivizumab for RSV 2022-23 Season Provider Letter - December 2022 update FINAL ○ SSC2468 – NICE notification letter- Guidance published December Final V1.0 ○ SSC2471- NICE TA FAD - Ixazomib with lenalidomide and dexamethasone for multiple myeloma ○ SSC2474 Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene in people 2 years and over who can walk (Review of HST3). ○ SSC2476 - NICE TA FAD: Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma [ID3901] ○ SSC2477 - Asfotase alfa for treating paediatric-onset hypophosphatasia (Review of HST6). ○ SSC2478 - NICE TA FAD: Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies. ○ SSC2482 - End of 2022-23 Respiratory Syncytial Virus (RSV) season and cessation of access to palivizumab passive immunisation against RSV in at risk pre-term infants ○ SSC2483 - Vestronidase alfa Mucopolysaccharidosis Type VII for (infants) ○ SSC2484 - NICE TA FAD: nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer ○ SSC2492 - NICE Technology Appraisal Guidance: TA855 Mobocertinib for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum- 	Enc.16.

	<p>based chemotherapy</p> <ul style="list-style-type: none"> ○ SSC2493 - NICE Technology Appraisal Final Appraisal Document: pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer ○ SSC2494 - Updated version of the Prescribed Specialised Services Manual published ○ SSC2495 - NICE Technology appraisal guidance TA858: Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma ○ SSC2496 - NICE Technology appraisal guidance TA857: Nivolumab with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma ○ SSC2497 - update on future NICE Appraisals that are due to be commissioned between May and June 2023. 	
13.	<p>Medicines Governance across the ICB</p> <ul style="list-style-type: none"> • Letter from Ewan Maule January 2023 • Letter from Ewan Maule 9th March 2023 • PowerPoint presentation 9th March 2023 • Nomination form for new committees 	Enc.17 - 20. (Previously circulated by email 17/1/23 and 13/3/23)
14.	Chairman's action	
15.	AOB	
16.	Next steps	